Skip to content
Search

Latest Stories

PSNC discusses with stakeholders impact of fuel crisis on community pharmacy

To discuss the ongoing fuel crisis and its impact on community pharmacy, Pharmaceutical Services Negotiating Committee (PSNC) held a meeting with stakeholders from across the supply chain, including the Department of Health and Social Care (DHSC) and NHS England and NHS Improvement (NHSE&I).

All agreed that the situation has started to improve, but acknowledged that some areas still remain affected by delays to deliveries of medicines.


The stakeholders also agreed that fuel crisis has increased the workload and stress levels for everyone across the supply chain and vowed to keep a watch on the evolving situations.

In addition to fuel crisis, the HGV driver shortages led to unpredictable deliveries of medicines into warehouses, creating logistics issues for wholesalers.

Meanwhile, the DHSC confirmed availability of sufficient stock of medicines within the supply chain.

PSNC director, legal, Gordon Hockey said: “The continued patient access to medicines throughout the fuel supply issues has been testament to the robustness of the medicines supply chain, as well as the incredible work of pharmacy teams and others across the supply chain to minimise the impact of any disruption.”

The meeting was also attended by representatives from organisations including the Royal Pharmaceutical Society (RPS), the National Pharmacy Association (NPA), the Association of Independent Multiples (AIMp), the Company Chemists Association (CCA), the General Pharmaceutical Council (GPhC) and the Consumer Healthcare Association (PAGB).

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less